Neurologix, Celladon, Then . . . ?
Phase II Gene-Therapy Wins: Father, Son Harvest Research
By Randy Osborne
Monday, June 28, 2010
Neurologix Inc.'s Phase II victory last week with NLX-P101 brought a much-needed credibility boost for gene therapy in Parkinson's disease and closely followed good news at the same clinical stage in advanced heart failure from Celladon Corp. with partner Targeted Genetics Corp.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.